AJGP
HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Geriatr Psychiatry 4:173-179, May 1996
© 1996 American Association for Geriatric Psychiatry
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a Colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berman, I.
Right arrow Articles by Losonczy, M. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Berman, I.
Right arrow Articles by Losonczy, M. F.

CLINICAL AND RESEARCH REPORT

Risperidone in Elderly Schizophrenic Patients

An Open-Label Trial

Ileana Berman, M.D., Amalia Merson, M.D., Julia Rachov-Pavlov, M.D., Edward Allan, M.D., Michael Davidson, M.D., and Miklos F. Losonczy, M.D., Ph.D.

Harvard Medical School.

The authors assessed the safety and efficacy of risperidone in a group of elderly patients with chronic schizophrenia and behavioral disturbances (N = 10). There were no clinically significant changes on physical examination. Also, schizophrenic symptoms and cognitive performance improved during risperidone administration. Patients showed a sufficient improvement in both areas to warrant a larger, double-blind study assessing the effects of risperidone on cognitive and psychiatric symptoms in elderly psychotic patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS
Copyright © 1996 American Association for Geriatric Psychiatry